Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 04 04:00PM ET
46.77
Dollar change
+0.55
Percentage change
1.19
%
IndexRUT P/E- EPS (ttm)-1.96 Insider Own11.68% Shs Outstand73.69M Perf Week1.28%
Market Cap3.45B Forward P/E- EPS next Y-1.74 Insider Trans-3.15% Shs Float65.09M Perf Month5.03%
Income-112.96M PEG- EPS next Q-0.52 Inst Own81.94% Short Float12.81% Perf Quarter48.71%
Sales23.39M P/S147.35 EPS this Y-13.12% Inst Trans15.16% Short Ratio8.14 Perf Half Y59.30%
Book/sh9.55 P/B4.90 EPS next Y21.59% ROA-21.78% Short Interest8.34M Perf Year169.26%
Cash/sh7.13 P/C6.56 EPS next 5Y- ROE-23.28% 52W Range13.29 - 47.74 Perf YTD31.45%
Dividend Est.- P/FCF- EPS past 5Y-2.95% ROI-18.15% 52W High-2.02% Beta0.81
Dividend TTM- Quick Ratio19.65 Sales past 5Y14.24% Gross Margin83.03% 52W Low251.92% ATR (14)1.70
Dividend Ex-Date- Current Ratio19.65 EPS Y/Y TTM-40.58% Oper. Margin-574.85% RSI (14)61.72 Volatility3.56% 3.87%
Employees124 Debt/Eq0.00 Sales Y/Y TTM-54.08% Profit Margin-483.05% Recom1.10 Target Price51.10
Option/ShortYes / Yes LT Debt/Eq0.00 EPS Q/Q-3.50% Payout- Rel Volume0.54 Prev Close46.22
Sales Surprise-55.64% EPS Surprise-11.18% Sales Q/Q-2.46% EarningsFeb 20 BMO Avg Volume1.02M Price46.77
SMA203.65% SMA5013.72% SMA20055.59% Trades Volume551,986 Change1.19%
Date Action Analyst Rating Change Price Target Change
Aug-08-23Initiated SVB Securities Outperform $33
May-24-23Initiated Goldman Buy $32
Apr-24-23Upgrade Stifel Hold → Buy $18 → $24
Mar-23-23Initiated Berenberg Buy $26
Feb-28-23Initiated RBC Capital Mkts Outperform $25
Dec-28-22Initiated CapitalOne Overweight $29
Oct-27-22Initiated Citigroup Buy $26
Aug-15-22Downgrade Stifel Buy → Hold $16 → $13
Jul-18-22Resumed Oppenheimer Outperform $25
Mar-10-22Upgrade Stifel Hold → Buy $27 → $20
Mar-04-24 06:00AM
Feb-20-24 06:36AM
06:00AM
Feb-13-24 05:37AM
Feb-01-24 06:00AM
06:00AM Loading…
Jan-26-24 06:00AM
Jan-18-24 01:03AM
Jan-15-24 07:03AM
Jan-07-24 09:00AM
Dec-29-23 06:00AM
Dec-08-23 06:00AM
Dec-05-23 06:00AM
Dec-04-23 06:00AM
Dec-03-23 09:00AM
Nov-14-23 09:55AM
07:15AM Loading…
Nov-07-23 07:15AM
06:44AM
06:00AM
Nov-01-23 06:00AM
Oct-27-23 04:02PM
06:00AM
Oct-25-23 11:55AM
Oct-24-23 10:15PM
04:07PM
Oct-23-23 06:00AM
Oct-18-23 08:33AM
Oct-17-23 06:00AM
Oct-16-23 06:00AM
Oct-09-23 06:00AM
Oct-06-23 06:00AM
06:00AM Loading…
Sep-27-23 06:00AM
Sep-26-23 06:00AM
Sep-15-23 01:03PM
Sep-11-23 06:00AM
Sep-05-23 06:00AM
Aug-21-23 06:00AM
Aug-16-23 06:00AM
Aug-10-23 07:15AM
06:00AM
Aug-08-23 10:02AM
Aug-02-23 06:00AM
Aug-01-23 06:00AM
Jul-28-23 06:00AM
Jun-30-23 06:00AM
Jun-22-23 06:00AM
Jun-12-23 06:00AM
Jun-11-23 09:56AM
May-30-23 06:00AM
May-26-23 06:00AM
May-22-23 06:00AM
May-16-23 06:00AM
May-09-23 07:25AM
06:00AM
May-04-23 10:00AM
May-02-23 10:02AM
May-01-23 06:00AM
Apr-29-23 09:00AM
Apr-28-23 06:00AM
Apr-27-23 04:01PM
Apr-25-23 05:44AM
12:15AM
Apr-24-23 04:12PM
12:13PM
Apr-23-23 09:00AM
Apr-19-23 06:00AM
Apr-16-23 09:50AM
Apr-03-23 06:00AM
Mar-31-23 06:00AM
Mar-27-23 09:55AM
Mar-14-23 04:31PM
Mar-07-23 07:15AM
06:00AM
Mar-01-23 06:00AM
Feb-16-23 06:00AM
Feb-01-23 06:00AM
Jan-23-23 06:00AM
Jan-09-23 06:00AM
Jan-03-23 06:00AM
Jan-01-23 08:50AM
Dec-19-22 06:00AM
Dec-12-22 06:00AM
Dec-05-22 09:55AM
06:00AM
Nov-29-22 06:00AM
Nov-28-22 06:00AM
Nov-17-22 01:58PM
Nov-16-22 09:55AM
Nov-10-22 05:02AM
Nov-08-22 07:35AM
06:00AM
Nov-01-22 06:00AM
Oct-18-22 09:09AM
06:00AM
Sep-21-22 06:52AM
Sep-19-22 04:01PM
Sep-14-22 10:41PM
04:39PM
Sep-13-22 11:18AM
Sep-12-22 01:22PM
Sep-11-22 05:00PM
IDEAYA Biosciences, Inc. engages in the research and development of oncology-focused precision medicine. The firm focuses on the targeted therapeutics for patients selected using molecular diagnostics. Its product candidate, IDE196, is a protein kinase C inhibitor for genetically defined cancers having GNAQ or GNA11 gene mutations. The company was founded by Yujiro S. Hata and Jeffrey Hager in June 2015 and is headquartered in South San Francisco, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Hata Yujiro SPresident and CEOFeb 09Option Exercise4.3123,557101,531701,444Feb 12 04:27 PM
Hata Yujiro SPresident and CEOFeb 09Sale45.5423,5571,072,715677,887Feb 12 04:27 PM
Ruiz Briseno AndresSee RemarksFeb 09Sale46.022,00092,04524,531Feb 13 04:59 PM
Hata Yujiro SPresident and CEOFeb 08Option Exercise4.3175,815326,763753,702Feb 12 04:27 PM
Hata Yujiro SPresident and CEOFeb 08Sale45.1575,8153,422,835677,887Feb 12 04:27 PM
Hata Yujiro SPresident and CEOFeb 01Option Exercise4.316282,707678,515Feb 05 06:05 PM
Hata Yujiro SPresident and CEOFeb 01Sale45.0062828,260677,887Feb 05 06:05 PM
Ruiz Briseno AndresSee RemarksJan 22Sale42.032,00084,05026,531Jan 24 07:12 PM
Hata Yujiro SPresident and CEOJan 16Option Exercise4.3162,739270,405740,626Jan 17 05:40 PM
Hata Yujiro SPresident and CEOJan 16Sale40.1762,7392,519,968677,887Jan 17 05:40 PM
Hata Yujiro SPresident and CEOJan 12Option Exercise4.3112,26152,845690,148Jan 17 05:40 PM
Hata Yujiro SPresident and CEOJan 12Sale40.0412,261490,913677,887Jan 17 05:40 PM
Ruiz Briseno AndresSee RemarksJan 12Sale38.012,00076,02628,531Jan 17 05:41 PM
Throne JasonChief Legal OfficerDec 18Option Exercise7.0110,00070,10010,000Dec 19 05:37 PM
Hata Yujiro SPresident and CEODec 15Option Exercise4.3175,000323,250752,887Dec 19 05:34 PM
Throne JasonChief Legal OfficerDec 15Option Exercise13.3410,000133,40010,000Dec 19 05:37 PM
Hata Yujiro SPresident and CEODec 15Sale35.0375,0002,627,618677,887Dec 19 05:34 PM
Throne JasonChief Legal OfficerDec 15Sale35.0410,000350,3710Dec 19 05:37 PM
Ruiz Briseno AndresSee RemarksDec 14Sale34.002,00068,00230,531Dec 18 05:45 PM
Throne JasonChief Legal OfficerNov 03Option Exercise12.865,16366,3965,163Nov 07 05:47 PM
Throne JasonChief Legal OfficerNov 03Sale30.095,163155,3600Nov 07 05:47 PM
Throne JasonChief Legal OfficerSep 12Option Exercise12.861,00012,8601,000Sep 14 05:23 PM
Throne JasonChief Legal OfficerSep 12Sale30.001,00030,0050Sep 14 05:23 PM
Throne JasonChief Legal OfficerSep 05Option Exercise12.861,73722,3381,737Sep 06 06:37 PM
Throne JasonChief Legal OfficerSep 05Sale30.031,73752,1600Sep 06 06:37 PM
Throne JasonChief Legal OfficerSep 01Option Exercise12.862,10027,0062,100Sep 06 06:37 PM
Throne JasonChief Legal OfficerSep 01Sale30.032,10063,0630Sep 06 06:37 PM
Ruiz Briseno AndresSee RemarksSep 01Sale30.012,00060,01632,531Sep 06 06:36 PM
Stone Paul A.Chief Financial OfficerAug 29Sale28.875,000144,3529,303Aug 31 05:49 PM
Stone Paul A.Chief Financial OfficerAug 21Sale26.4097825,81914,303Aug 23 06:31 PM
Stone Paul A.Chief Financial OfficerAug 18Sale26.383,822100,82015,281Aug 18 06:33 PM
Stone Paul A.Chief Financial OfficerAug 16Sale26.432005,28519,103Aug 18 06:33 PM
Throne JasonChief Legal OfficerAug 09Option Exercise13.345,00066,7005,000Aug 11 07:22 PM
Throne JasonChief Legal OfficerAug 09Sale25.095,000125,4300Aug 11 07:22 PM
Stone Paul A.Chief Financial OfficerAug 09Sale25.052,50062,61319,303Aug 11 07:21 PM
Throne JasonChief Legal OfficerJul 10Option Exercise10.099,48595,7409,485Jul 12 05:25 PM
Throne JasonChief Legal OfficerJul 10Sale23.009,485218,1780Jul 12 05:25 PM
Throne JasonChief Legal OfficerJun 01Option Exercise7.013,55324,9073,553Jun 02 05:29 PM
Throne JasonChief Legal OfficerJun 01Sale23.023,55381,7920Jun 02 05:29 PM
Throne JasonChief Legal OfficerMay 31Option Exercise7.014323,028432Jun 02 05:29 PM
Throne JasonChief Legal OfficerMay 31Sale23.004329,9380Jun 02 05:29 PM
Throne JasonChief Legal OfficerMay 22Option Exercise7.015003,505500May 24 05:51 PM
Throne JasonChief Legal OfficerMay 22Sale23.0050011,5000May 24 05:51 PM
Stone Paul A.Chief Financial OfficerApr 13Option Exercise4.628,00036,96021,803Apr 14 01:20 PM
Hata Yujiro SPresident and CEOApr 12Option Exercise4.3111,60150,000677,887Apr 13 04:11 PM